| Not Yet Recruiting | ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic M NCT07518940 | Carmen Fava | N/A |
| Not Yet Recruiting | A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) NCT07429266 | Ono Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera NCT06290765 | PharmaEssentia | Phase 4 |
| Recruiting | A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes NCT07203768 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Recruiting | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) NCT06661915 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) NCT07012109 | BeBetter Med Inc | Phase 1 |
| Not Yet Recruiting | Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History NCT06923670 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Not Yet Recruiting | EVAluation of Erythrocytosis PRospEctive Cohort STudy NCT06785870 | Cyrus Hsia | — |
| Recruiting | Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly NCT06743035 | iOMEDICO AG | — |
| Recruiting | LOW-PV Continuation NCT06752941 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Recruiting | Efficacy and Safety of Peginterferon in ET and PV. NCT06734637 | Zhenya Hong | N/A |
| Not Yet Recruiting | Real-world Ruxolitinib Experience in PV NCT06251102 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes NCT06361641 | University Hospital, Angers | N/A |
| Recruiting | A Study of GLB-001 in Patients With Myeloid Malignancies NCT06378437 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition NCT06218628 | Fox Chase Cancer Center | Phase 1 |
| Recruiting | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera NCT06093672 | Italfarmaco | Phase 3 |
| Recruiting | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients NCT06752746 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Recruiting | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, NCT06063486 | University of Southern California | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera NCT06033586 | Protagonist Therapeutics, Inc. | Phase 3 |
| Completed | A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004) NCT05558696 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Phase 2 |
| Terminated | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors NCT05853458 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV NCT05870475 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773 | The University of Hong Kong | — |
| Active Not Recruiting | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycyt NCT05548062 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Study to Assess SLN124 in Patients With Polycythemia Vera NCT05499013 | Silence Therapeutics plc | Phase 1 / Phase 2 |
| Unknown | Hematocrit to Hemoglobin Ratio and Red Blood Cell Distribution Width in Polycythemia Vera and Secondary Erythr NCT05993065 | Sohag University | — |
| Active Not Recruiting | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV NCT05481151 | PharmaEssentia | Phase 3 |
| Unknown | Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice NCT05566535 | Multinational Center for Quality of Life Research, Russia | — |
| Active Not Recruiting | Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) NCT06506084 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Unknown | Safety Evaluation Study for Patients With Polycythemia Vera NCT05074550 | Perseus Proteomics Inc. | Phase 1 |
| Recruiting | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V61 NCT05198960 | University Hospital, Brest | Phase 3 |
| Active Not Recruiting | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera NCT05210790 | Protagonist Therapeutics, Inc. | Phase 3 |
| Recruiting | Ruxolitinib in Thrombocythemia and Polycythemia Vera NCT04644211 | Massachusetts General Hospital | Phase 2 |
| Recruiting | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms NCT05123365 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU NCT05485948 | PharmaEssentia | Phase 2 |
| Completed | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With P NCT04629508 | Incyte Corporation | Phase 2 |
| Withdrawn | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leu NCT04896112 | Lynk Pharmaceuticals Co., Ltd | Phase 1 |
| Completed | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit NCT04767802 | Protagonist Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) NCT04262141 | Terrence J Bradley, MD | Phase 2 |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Recruiting | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia NCT04116502 | University of Birmingham | Phase 3 |
| Completed | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) NCT04057040 | Protagonist Therapeutics, Inc. | Phase 2 |
| Completed | Dual Vaccine Trial in Myeloproliferative Neoplasms NCT04051307 | Inge Marie Svane | Phase 1 / Phase 2 |
| Terminated | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia NCT03972943 | University of Utah | EARLY_Phase 1 |
| Active Not Recruiting | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT03862157 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myelop NCT03878199 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Unknown | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera NCT03669965 | Kartos Therapeutics, Inc. | Phase 2 |
| Completed | Clinical and Laboratory Characteristics of Polycythemia Vera NCT06134102 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase NCT03907436 | University of California, Irvine | N/A |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) NCT03745378 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | — |
| Terminated | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in NCT03287245 | Hoffmann-La Roche | Phase 2 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms NCT03065400 | John Mascarenhas | Phase 2 |
| Terminated | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms NCT03121599 | Hamad Medical Corporation | N/A |
| Completed | Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms NCT02823184 | University Hospital, Bordeaux | — |
| Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms NCT06371573 | Federico II University | — |
| Completed | The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV NCT03003325 | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Phase 2 |
| Completed | Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure NCT02912884 | Dr Yan Beauverd | — |
| Unknown | Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features NCT02809274 | Rambam Health Care Campus | — |
| Withdrawn | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelof NCT02805868 | Northwestern University | EARLY_Phase 1 |
| Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders NCT02663648 | Shandong University | — |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | Myeloproliferative Neoplastic Diseases Observatory From Brest NCT02897297 | University Hospital, Brest | — |
| Completed | A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera NCT05853445 | Novartis Pharmaceuticals | — |
| Completed | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Ve NCT02523638 | AOP Orphan Pharmaceuticals AG | Phase 3 |
| Completed | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea NCT02493530 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Completed | Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia NCT02407080 | John Mascarenhas | Phase 1 |
| Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238 | University Health Network, Toronto | — |
| Completed | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation NCT02311569 | Swiss Cancer Institute | Phase 2 |
| Active Not Recruiting | CINC424A2X01B Rollover Protocol NCT02386800 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients NCT02893410 | University Hospital, Brest | — |
| Completed | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resis NCT02292446 | Novartis Pharmaceuticals | Phase 3 |
| Completed | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. NCT02218047 | AOP Orphan Pharmaceuticals AG | Phase 3 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera My NCT02124746 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Completed | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Availabl NCT02038036 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia NCT01998828 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Completed | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis NCT01981850 | Hoffmann-La Roche | Phase 2 |
| Completed | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Ver NCT01901432 | Italfarmaco | Phase 1 / Phase 2 |
| Completed | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera NCT01949805 | AOP Orphan Pharmaceuticals AG | Phase 3 |
| Completed | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF NCT01787552 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Myeloproliferative Neoplasms: an In-depth Case-control Study NCT01831635 | Queen's University, Belfast | — |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients NCT01970930 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms NCT01520220 | Eli Lilly and Company | Phase 1 |
| Completed | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief S NCT01632904 | Incyte Corporation | Phase 3 |
| Unknown | Myeloproliferative Neoplasms and Bone Structure NCT01816022 | University of Southern Denmark | — |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms NCT01387763 | Thomas Stauffer Larsen | Phase 3 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycyth NCT01243073 | Geron Corporation | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: NCT01243944 | Incyte Corporation | Phase 3 |
| Completed | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera NCT01193699 | AOP Orphan Pharmaceuticals AG | Phase 1 / Phase 2 |
| Completed | A Study in Myeloproliferative Disorders NCT01134120 | Eli Lilly and Company | Phase 1 |
| Terminated | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis NCT01014546 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Terminated | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera NCT01038856 | University of Oklahoma | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pomalidomide for Myelofibrosis Patients NCT00946270 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Natural Killer Cells and Polycythemia Vera (Vaquez's Disease) NCT01284712 | Assistance Publique Hopitaux De Marseille | — |
| Withdrawn | Clopidogrel and Aspirin for the Treatment of Polycythemia Vera NCT00940784 | Ronald Hoffman | Phase 2 |
| Completed | Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera NCT00928707 | Italfarmaco | Phase 2 |
| Unknown | A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia NCT00866762 | Copenhagen University Hospital at Herlev | Phase 2 |
| Completed | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis NCT00745550 | S*BIO | Phase 1 / Phase 2 |
| Terminated | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) NCT01645124 | Consorzio Mario Negri Sud | Phase 3 |
| Unknown | CEP-701 (Lestaurtinib) in Myelofibrosis NCT00668421 | Ronald Hoffman | Phase 1 / Phase 2 |
| Completed | Familial Myeloproliferative Disorders NCT00666289 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Phase 1 Study of XL019 in Adults With Polycythemia Vera NCT00595829 | Exelixis | Phase 1 |
| Completed | Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis NCT00586651 | Cephalon | Phase 2 |
| Completed | Research Tissue Bank NCT00666549 | Icahn School of Medicine at Mount Sinai | — |
| Terminated | A Safety Study of XL019 in Adults With Myelofibrosis NCT00522574 | Exelixis | Phase 1 |
| Completed | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thromb NCT00509899 | Incyte Corporation | Phase 1 / Phase 2 |
| Terminated | Dasatinib in Polycythemia Vera NCT00538980 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Correlative Biomarker Study in Patients With Myeloproliferative Disorders NCT00665067 | Icahn School of Medicine at Mount Sinai | — |
| Completed | Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders NCT00433862 | National Institutes of Health Clinical Center (CC) | — |
| Completed | Effects of Imatinib Mesylate in Polycythemia Vera NCT00430066 | Niguarda Hospital | Phase 2 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Completed | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes NCT00715247 | University of Utah | — |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis NCT00227591 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) NCT00255346 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera NCT00241241 | PV-Nord | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leuke NCT00052520 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Treatment of Polycythemia Vera With Gleevec NCT01120821 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia NCT00047190 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Myelofibrosis NCT00039416 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and NCT00038675 | M.D. Anderson Cancer Center | N/A |
| Completed | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies NCT01499147 | University of Illinois at Chicago | N/A |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| No Longer Available | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera NCT05269771 | Novartis Pharmaceuticals | — |